Christel Franchet
Corporate Officer/Principal chez Domain Therapeutics SA
Profil
Christel Franchet is the founder of Euroclide SA, which was founded in 2001.
She is currently the Head of Biology Department at Domain Therapeutics SA. Dr. Franchet's former position was as a Principal at Hoffmann La Roche France in 2001.
She received a doctorate degree from the University of Strasbourg in 2001.
Postes actifs de Christel Franchet
| Sociétés | Poste | Début |
|---|---|---|
Domain Therapeutics SA
 Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Corporate Officer/Principal | - |
Anciens postes connus de Christel Franchet
| Sociétés | Poste | Fin |
|---|---|---|
| Hoffmann La Roche France | Corporate Officer/Principal | 01/01/2001 |
Euroclide SA
 Euroclide SA Miscellaneous Commercial ServicesCommercial Services Part of Domain Therapeutics SA, Euroclide SA is a French drug research company. The company was founded by Christel Franchet. Euroclide was acquired by Domain Therapeutics SA on December 22, 2003. | Fondateur | - |
Formation de Christel Franchet
| University of Strasbourg | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Health Technology |
Euroclide SA
Euroclide SA Miscellaneous Commercial ServicesCommercial Services Part of Domain Therapeutics SA, Euroclide SA is a French drug research company. The company was founded by Christel Franchet. Euroclide was acquired by Domain Therapeutics SA on December 22, 2003. | Commercial Services |
| Hoffmann La Roche France |